In 2018 more than a quarter of medtech funding came from rounds in which corporate VCs took part.
The J&J-Auris tie-up will yield a huge return for investors who went in big.
Johnson & Johnson’s $3.4bn move for the robotic surgery specialist Auris Health could be bad news for its Verb Surgical joint venture.
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
In a truly extraordinary year, the top 10 venture rounds made up more than half of the total invested.
Vast amounts of venture cash are available to medical device makers, but its distribution is uneven.
So far, 2017 has been a record-breaker in a number of ways – and none of them bode well for start-ups.